BIOAGE LABS, INC. Shareholders' Equity
BIOAGE LABS, INC. (BIOA) had Shareholders' Equity of $374.91 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $374.91M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $379.12M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $272.05M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $277.46M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $374.91M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $379.12M 10-Q · filed 2026-08-05 |
| 2025-12-31 | $272.05M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $277.46M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $294.78M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $313.17M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $323.13M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $313.75M 10-Q · filed 2025-11-06 |
| 2024-06-30 | -$197.13M 10-Q · filed 2025-11-06 |
| 2024-03-31 | -$185.51M 10-Q · filed 2025-11-06 |
| 2023-12-31 | -$173.40M 10-K · filed 2026-03-24 |
| 2023-09-30 | -$153.14M 10-Q · filed 2024-11-07 |
| 2023-06-30 | -$139.31M 10-Q · filed 2024-11-07 |
| 2023-03-31 | -$122.92M 10-Q · filed 2024-11-07 |
| 2022-12-31 | -$112.56M 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |